



Investor
Presentation

May 2024

FORWARD LOOKING STATEMENTS

This presentation has been prepared by Movano Inc. dba Movano Health (“we,” “us,” “our,” “Movano” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither this presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; product development efforts and product releases; clinical trial and regulatory initiatives; commercial partner activities; as well as our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption “Risk Factors.” Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

PIVOTAL CAPITAL RAISE COMPLETED



STRATEGIC SEED INVESTMENT

- Tier 1 multi-billion dollar medical device company
- \$3M equity investment
- Agreement underscores our proprietary, multi-analyte mmWave RF technology
- Recent blood pressure (BP) clinical trial results were a catalyst to the strategic investment



**April 2024
Financing
Closed!**



\$24M PIPE FINANCING

- Private Placement of 45M units, \$24M gross proceeds, extending cash runway
- Use of proceeds:
 - Scale Evie Ring (D2C)
 - FDA clearance decision and B2B commercial relationships
 - Accelerate development of RF technology (including BP)

CATALYSTS AHEAD IN 2024



1

Optimize Evie Ring to
Scale D2C



2

FDA Clearance
Expected July 2024



3

Launch B2B
Commercial
Operations



4

Accelerate RF
Technology
Development

EVIE RING: STRONG D2C PROPOSITION



Rings are the
it formfactor



The Verge

CES / WEARABLE / TECH

This might be the year of the smart ring / I saw more smart rings on the CES show floor than I have in years. The Oura Ring might have some real competition soon.

By [Victoria Song](#), a senior reporter focusing on wearables, health tech, and more with 11 years of experience. Before coming to The Verge, she worked for Gizmodo and PC Magazine.
Jan 12, 2024, 8:00 AM EST

Scale
through
2024



Evie is the only
product focused
on women



\$1M in Black
Friday sales




Consistent
organic
demand



WEARABLE MARKET GROWING EXPONENTIALLY

\$145B GLOBAL
WEARABLE
MARKET BY 2027¹



EVIE'S JOURNEY

From **IDEA** to
COMMERCIAL PRODUCT
in 24 months

2024



Evie live at CES
(D2C)



First capital
investment from
Strategic Partner

- catalyst rich year ahead -



Scale Evie Ring
(D2C)



Expected FDA
clearance (July)



Initial B2B
commercial
agreements



Blood Pressure
clinical trials

2023



Brand unveiled
at CES



Pilot B2B
relationships



First FDA submission for
Evie's pulse oximeter



Product launched!



\$1M in Black Friday sales -
organic; limited paid media

2022



Establish the team



Start building the
technology

Q4 - 2021



IDEA - develop
a smart ring for
women's health

THE EVIE RING FILLS A UNIQUE NEED NOT CURRENTLY ADDRESSED



WOMEN-FOCUS

NO EXISTING SOLUTION

- Form factor and sizing designed for women
- Personalized insights derived from AI
- Gamify the process of getting healthier
- Menstrual health prioritized for all stages
- Mental health correlated with passively-collected ring data
- Medical grade technology
- Blood pressure and glucose monitoring



ENTERPRISE

NO EXISTING SOLUTION

- Pharma needs a medical-grade device for clinical trials and post-market surveillance
- Medical device companies need patient status for real-time optimization
- Payors need medical-grade Remote Patient Monitoring (RPM) capabilities
- Retailers are looking for health narrative

FITNESS & WELLNESS

INCUMBENT PRODUCTS ARE ONE-SIZE-FITS-ALL

- Serve fitness enthusiasts
- Focus on comms, staying connected
- Quantitatively track performance metrics
- Bring awareness to sleep duration and stages



uniquely positioned to satisfy these market needs

STRONG ENGAGEMENT AND DEMAND DESPITE INITIAL LAUNCH CHALLENGES



>1B
Media Impressions
Since CES

150K
Total Email
Sign Ups

18K
Social Media
Followers



Home / Tech / Wearables

The best smart rings you can buy: Expert tested

Smart rings are the next big wearable. I tested the top smart rings to find out which was the best.



/ tech



Evie Ring
Best smart ring for women



Bustle

30 Game-Changing Items You'll
Want To Buy This Spring

A New Smart Ring



Evie Ring

Evie

\$269

Size and Color

The O List: Winter Wellness

We have just what you need to help you relax, relate, and release.



14
Evie Ring

\$269 AT EVIERING.COM



WOMEN'S HEALTH FOCUS: IT'S ABOUT TIME



\$44B

2023 US Market Size: Women's Health¹

\$100M

White House Investment in Women's Health²


1000+

Women interviewed to design Evie

1. <https://www.grandviewresearch.com/industry-analysis/womens-health-market>

2. <https://www.whitehouse.gov/briefing-room/speeches-remarks/2024/02/21/remarks-as-prepared-for-delivery-by-first-lady-jill-biden-to-announce-the-100-million-arpa-h-sprint-for-womens-health/>

EVIE US MARKET TAM & COMPOSITION



27% of Women Surveyed Answered "Extremely or Very Likely" to Buy¹

~33M WOMEN

WE HAVE INSIGHT TO HEALTH ISSUES...

Insomnia

Depression

Heart Disease

Menopause/ Fertility

...AND HOW WE'LL TARGET THEM

Clinical Trials

Corporate Wellness

Traditional Media

Paid Advertisement

1. MH survey, 33M TAM based on US Population 2023, women ages 18+ extremely or very likely to buy

KEY EVIE RING DIFFERENTIATORS



1

Sleek, Smart, Comfortable Hardware

- Open ring design offers comfortable fit
- Rated most aesthetically pleasing smart ring (*Wall Street Journal*)
- Small portable recharging case

2


Novel App Design

- Seamlessly tracks key biometric data including menstrual cycle, mood, energy
- Personalized activity and performance goals
- Industry first Daily Summary dynamically displays daily progress

3

AI-Driven Insights

- Identifies correlations, patterns and trends across different vital signs, menstrual health, mood, energy, sleep and activity in longitudinal data




Got it

Got it


SNEAK PEAK: EVIE APP INSIGHTS EXPERIENCE



Passively collected
body data on sleep



Logged symptom +
cycle data



Educational insight based
on her experience



HOW EVIE RING STACKS UP



	Steps & Activity	Sleep & Sleep Stages	Heart Rate (HRV, RHR)	SpO2	Skin Temp.	Menstrual Cycle	Mood Logging	Personal Insights	Form Factor/ Finishes	Price
	●	●	●	⊘*	●	●			Bands & Watches	\$99-\$299
WHOOP®	●	●	●	⊘*	●	●			Screenless Bands	\$20/month with 1-year commit
OURA	●	●	●	⊘*	●	●			Gold, Silver, Rose Gold, Black	\$299-\$549 & \$6/month sub
	●	●	★	★	●	●	●	●	Gold, Silver, Rose Gold	\$269

★ Potential for FDA clearance ● Full function ⊘ Limited function

*Fitbit, Whoop, and Oura devices make nighttime readings only.

EVIE MED: STRONG B2B PROPOSITION



ET Healthworld.com
From The Economic Times

Health IT · 5 Min Read

Top 5 Technology Trends Shaping Modern Healthcare in 2024

Internet of Medical Things (IoMT) and Wearable Devices

The Internet of Medical Things (IoMT) refers to the interconnected network of medical devices and applications that collect, transmit, and analyse health data.

Expected FDA clearance decision by July 2024



Only FDA-cleared option for enterprises



New distribution channel



Attractive margin profile on B2B sales



First B2B investment + several beta programs underway




THE FIRST SMART RING TO FILE FOR FDA CLEARANCE ON SpO₂ & HR




Q1'24 HYPOXIA PIVOTAL TRIAL RESULTS

	SpO ₂ RMSE ¹	HR RMSE ²
FDA Benchmark	<3.5%	Within 2 bpm
Masimo - Radical-7	3.6%	1.5 bpm
Evie Rings (4)	2.39-2.53%	1.2 bpm




SpO₂




Heart Rate

1. Arterial blood gas used as reference, 2. Nellcor OxiMax N-595 used as reference

MOVANO HEALTH'S B2B OPPORTUNITY



CURRENT B2B ENGAGEMENTS ACROSS THE HEALTHCARE CONTINUUM



USE CASE #1 – Pharmaceutical Companies



Pharma / Clinical Trials

PROBLEM

- Poor compliance
- Suboptimal trial results
- In-person monitoring is expensive

SOLUTION

- Movano device usage enables better compliance
- Cost of device and monitoring significantly lower than regular office visits
- Movano device enables quicker enrollment, better data, and improved quality of results

TRACTION

- “Major global pharma” Beta I partner
- “Major global pharma” hosts >30,000 patients in clinical trials per year

GROWTH

- 5 near-term pharma clients in pipeline

USE CASE #2 – Payors



Payors

PROBLEM

- Large populations of chronic disease patients
- Costly disease interventions being deployed in cases that could be prevented
- Suboptimal evaluation of economic value associated with some interventions

SOLUTION

- Easy-to-implement monitoring of critical physical health parameters (sleep, blood oxygen, blood pressure, etc.)
- Potential for early detection of dangerous health risks
- Provides longitudinal health data

TRACTION

- “Top 3 US payor” Beta II partner
- “Top 3 US payor” covers 47M lives
- 20% of subscribers are high risk, just 5% of that group represents 500k units

GROWTH

- 2 near-term payor customers in pipeline

USE CASE #3 – Remote Patient Monitoring (RPM)



Remote Patient Monitoring (RPM)

PROBLEM

- Increasing needs to monitor patients remotely, due to broad lifestyle shifts and preferences
- In-office visits involve high cancellations; higher costs for patients and slower throughput for physicians
- Reduced frequency of physician monitoring promote suboptimal health monitoring

SOLUTION

- Regular monitoring reduce costs of healthcare
- Any device or component of an RPM solution must be FDA approved/cleared
- Improves access to healthcare (for patients of limited means, rural areas, complex needs, etc.)

TRACTION

- “Leading US RPM company” Beta II partner
- “Leading US RPM company” serves >450 healthcare organizations and is the exclusive platform for one of the largest medical device companies in the world

GROWTH

- 2 near-term RPM customers in pipeline

USE CASE #4 – Medical Device Patient Management



Medical Devices (Patient Management)

PROBLEM

- Inability to continuously monitor patients outside physician's office
- Suboptimal patient outcomes
- In-person monitoring is expensive

SOLUTION

- Ability to make real-time adjustments to patient regimen, improving outcomes
- Continuous data feed provides physicians better intelligence
- Reduces friction and cost to delivery patient care

TRACTION

- "Leading med device company" has engaged in initial draft of LOI
- "Leading med device company" serves >200k new patients/devices per year

GROWTH

- 5 near-term medical device customers in pipeline

MEDICAL DEVICE POSITIONING CREATES SIGNIFICANT BARRIERS TO ENTRY IN ENTERPRISE MARKET



To Compete With Movano Health, Companies Would Have To...

1

Create Medical Device Infrastructure

- Implement a Quality Management System (QMS)
- Hire medical device personnel for Quality, Regulatory, and Clinical (QRC)
- Train every employee on Standard Operating Procedures

2

Pursue FDA Clearance

- Establish clinical trials, generate all required documents
- Set up production to comply with FDA Good Manufacturing Practices

3

Establish Post Market Surveillance Functions

- Ongoing QRC initiatives to track product, complaints, CAPAs

Transitioning an existing wearables operation into a medical device company would be **extremely costly** and take **several years to execute**

MATERIAL PROGRESS WITH PROPRIETARY AND PATENTED RF TECHNOLOGY



Why High Blood Pressure Is Known as the Silent Killer

Peter Attia, M.D., author of 'Outlive: The Science & Art of Longevity,' shares how aggressively managing your blood pressure is a key to a longer and healthier life.



Blood pressure & glucose are "holy grail" opportunities



Commercial product in 2+ years



Proprietary RF technology de-risked



Strategic investment validates tech and opportunity



Recent BP clinical results unlock opportunity




BREAKTHROUGH IN BLOOD PRESSURE MONITORING WITH CLINICAL RESULTS IN LINE WITH AN FDA RECOGNIZED STANDARD



	Mean Absolute Difference
FDA Recognized Standard	7.0 mmHg ¹
Movano	5.9 mmHg²

- Cuffless wrist worn device
- Clinical study in 43 subjects
- BP measurements at rest and under stress

Q3'23 Blood Pressure (BP) Clinical Results



¹ Mean Absolute Difference (MAD) required per IEEE 708a-2019 standard for wearable, cuffless blood pressure measuring devices

² Company's algorithm for blood pressure monitoring utilized data from its prototype system combined with the subject's demographic information and a recent blood pressure reading

Movano Health patent summary

US: 27 Issued, 18 Pending (4 allowed)

Foreign: 1 Issued (China),
4 Pending (1 China/3 Europe)
PCT: 1 Pending

KEY US PATENTS FALL INTO FOUR CATEGORIES

RF IC Architecture (2) Issued

Covers RF IC design, including multi-band mixing and conductor loss mitigation that is critical at high frequencies.

Key Issued Patents:

- Systems for multi-band radar-based sensing (US 11,298,037)
- Methods for multi-band radar-based sensing (US 10,874,314)

Ring (3) Pending

Covers various aspects of the current Evie Ring and charger design, including the 2-piece open-ended construction, production efficiencies, and control efficiencies.

Pending Patents:

- Finger wearable health monitoring device
- Finger wearable devices and methods for producing finger wearable devices
- Ring charging case



RF-Based Health Monitoring (22) Issued (9) Pending

Covers signal processing techniques for generating high resolution pulse wave signal to determine HR, BP, BG level.

Key Issued Patents:

- Systems for RF-based health monitoring utilizing amplitude and phase data (US 11,445,929)
- Methods and systems for monitoring BP using stepped frequency radar with spectral agility (US 11,360,188)
- System for monitoring a physiological parameter that involves coherently combining data from RF-based sensor system (US 11,883,132)
- System for monitoring a health parameter of a person utilizing a pulse wave signal (US 11,786,133)

Machine Learning Applications (3) Issued (6) Pending

Techniques for generating training data and training ML models for health monitoring, and techniques for utilizing ML models for health monitoring, including blood pressure and blood glucose.

Key Issued Patents:

- Methods for training a model for use in RF-based health monitoring (US 11,464,419)
- Methods for training a model for use in radio waved based blood pressure monitoring (US 11,596,321)

CORPORATE SNAPSHOT (NASDAQ: MOVE)



DOLLARS RAISED

\$130M*

YEAR FOUNDED

2018

IP PORTFOLIO:

US 27 patents issued, 18 pending
OUS 1 patent issued, 5 pending

LTM CASH BURN 3/31/24

\$24M

NUMBER OF FTES

30

CASH AT 3/31/24

\$2.1M

\$24.8M *pro forma***

CORPORATE ENTITIES:

Movano Inc. dba
Movano Health
Movano Ireland



* In August 2022, the Company entered into an At the Market Issuance Agreement with B. Riley Securities, Inc. Pursuant to the terms of the Issuance Agreement, the Company may sell from time to time through the Sales Agent shares of the Company's common stock having an aggregate offering price of up to \$50M.

** *Pro forma* for \$24M gross proceeds raised in the April 2024 PIPE transaction.

NASDAQ: MOVE

+1 (415) 651-3172

6800 Koll Center Pkwy.
Pleasanton, CA 94566

www.movanohealth.com
www.eviering.com

